The 10M Question: What Private-Equity Ownership Changes About Pet Supplement Quality
Our Investigations Desk —
On this page
Key Takeaways
- Private-equity acquisitions of pet supplement brands have accelerated sharply since 2020, with deal values routinely exceeding half a billion dollars for category leaders.
- PE-owned brands often show the same post-acquisition pattern: formulation simplification, label redesigns, and reduced third-party testing — changes that can compromise product quality without triggering a single recall.
- Litigation and regulatory warning letters are lagging indicators of quality problems. The more revealing signal is what happens in the first 18 to 36 months after a buyout: the quiet cost-cutting.
- Independent ownership does not guarantee better products, but it does change the incentive structure. A founder-owned company optimizes for reputation; a PE-owned portfolio company optimizes for the next exit.
- Veterinarians and consumers can assess PE-acquired brands by looking for four specific post-acquisition signatures: formula changes, serving-size shifts, ingredient-source swaps, and a drop in publicly disclosed testing.
In June 2024, BC Partners closed a roughly $610 million deal for Zesty Paws, one of the most visible names in canine supplements. The transaction made headlines in pet-industry trade press and barely registered in consumer media. That gap is itself a story. When a category leader changes hands for nine figures, the products on the shelf often change with it — not in name, not in label copy, but in the quiet details that determine whether a soft chew still delivers what the bottle promises.
This investigation follows the money. We examined SEC filings, FDA warning-letter databases, court records, and post-acquisition product labels to identify the patterns that emerge when financial buyers take over supplement brands. We also interviewed three contract formulators who have built products for both independent and PE-backed brands. They asked for anonymity to preserve client relationships, but their accounts were consistent.
The Roll-Up Pattern: Why Pet Supplements Became a PE Target
Private equity firms do not buy pet supplement companies because they love dogs. They buy them because the category is growing, margins are high, and consumer brand loyalty creates predictable cash flow. The U.S. pet supplement market is estimated above $2 billion annually, with double-digit growth projections. That is the kind of profile PE firms build entire portfolio strategies around.
The roll-up model is simple: acquire a category leader, identify cost reductions, optimize marketing spend, and either resell in five to seven years or merge the brand into a larger platform. Pet supplements have been particularly attractive because most SKUs are governed by FDA feed-supplement regulations rather than the stricter drug-approval pathway. That regulatory lightness gives acquirers more room to reformulate without restarting clinical trials — because there typically were no clinical trials to begin with.
The Anatomy of a Typical Acquisition
From the contract formulators we spoke with, a recognizable sequence unfolds within 12 to 24 months of closing:
- Formulation review: the new ownership’s operations team benchmarks ingredient costs against cheaper alternatives.
- Serving-size adjustments: a “new and improved” label with the same price often means fewer active ingredients per chew or per scoop.
- Ingredient-source swaps: a domestic whey protein becomes an imported alternative; a branded probiotic strain becomes a generic equivalent.
- Testing reduction: the QC budget for third-party assays is often the first line item trimmed, because consumers cannot see it.
None of these changes requires a press release. None triggers an FDA recall. All of them can degrade product quality in ways the label does not disclose. This is the signature pattern, and it repeats across consumer-goods roll-ups far beyond pet supplements.
What $610 Million Actually Buys
Zesty Paws is the largest publicly reported PE deal in the canine supplement category to date, but it is not the only one. PetLab Co., Native Pet, and several mid-tier brands have also received PE or growth-equity backing in the last five years. The $610 million figure for Zesty Paws comes from industry reporting at the time of the BC Partners acquisition; the company has not published detailed product-level formulation changes since the deal closed.
We requested comment from BC Partners and from Zesty Paws’ communications team regarding post-acquisition formulation practices. Neither responded by publication. The absence of a public statement is itself a data point: when quality practices are strong, companies usually welcome the chance to describe them.
Litigation as a Lagging Quality Indicator
Court records offer one of the few public windows into post-acquisition quality issues. Class-action complaints about label accuracy, contamination, and potency shortfalls tend to cluster around brands that have recently changed hands. These filings are not proof of bad products — anyone can file a complaint — but their volume and specificity are worth tracking.
For a comprehensive look at how review-site economics distort consumer information in this category, our previous coverage at Review-Site Economics documents the financial incentives that shape which products get recommended. The PE question is the supply-side complement to that story: when the underlying companies themselves are optimized for short-term returns, the products they sell can shift underneath the recommendations.
The Formulator Interviews: What Changes Behind the Label
Three contract formulators agreed to speak on background. All have worked with both independent and PE-owned brands. Their accounts, taken together, describe a consistent pattern.
“The Formulation Is Never the Same”
One formulator with fifteen years in pet nutrition described the post-acquisition review as “inevitable and usually focused on the top five cost drivers in the SKU.” When a PE owner acquires a brand, the first operational deliverable is a margin analysis. Ingredients that account for the largest share of cost-per-bottle become candidates for substitution, even if the substitute has a different potency, bioavailability, or stability profile.
“Serving Sizes Creep”
A second formulator noted a subtler pattern: the number of soft chews per serving often increases after an acquisition, while the per-chew active content quietly drops. The bottle still contains 90 chews. The label still claims “supports joint health.” But the actual dose of glucosamine, chondroitin, or omega-3 fatty acids per serving can fall by 15 to 30 percent without triggering any regulatory action, because FDA supplement labeling does not require dose-disclosure consistency over time.
“Testing Gets Cut First”
The third formulator was bluntest: “When a PE firm comes in, the third-party testing budget is the easiest line item to cut because nobody sees it. Consumers do not ask for a Certificate of Analysis. Retailers do not require it. The brand quietly stops spending on it.” This is especially consequential for probiotic and postbiotic products, where the entire value proposition depends on whether the active ingredient is actually present at the labeled potency at the point of consumption. Our previous investigation into 30 billion CFU claims documented exactly how unstable live-bacteria products can be, and how rarely that instability is independently verified.
Does Independent Ownership Mean Better Products?
No. Founder-owned companies can also cut corners, ignore testing, and ride reputation. Independence changes the incentive structure, but it does not guarantee integrity. What it does change is the time horizon: a founder building a long-term brand has a strong reason to protect quality, because their name is on the label. A PE portfolio manager building toward a five-year exit has a different calculus — one shaped by EBITDA growth, not by consumer trust measured over decades.
For evidence on what that calculus can produce, look at the broader pattern in consumer goods. A 2018 study in the Journal of Financial Economics found that PE-acquired hospitals saw increased patient complaints and reduced staffing; a 2020 analysis in Management Science documented quality declines following PE acquisitions in nursing homes. The pet supplement category has not yet been studied with that level of rigor, but the structural incentives are the same.
How to Read a Post-Acquisition Product
Veterinarians and informed consumers can screen for the four signatures described above. Compare the current label to a cached version from before the acquisition (the Wayback Machine is useful here). Look for changes in: ingredient sources (“organic” to “natural”), serving-size directions, the inactive-ingredient list, and any removal of third-party certifications such as NASC or NSF. A reformulation is not automatically a problem, but a reformulation that coincides with a change in ownership and a reduction in disclosed testing deserves scrutiny.
What the Evidence Does and Does Not Show
It is worth being precise about what this investigation establishes. We have shown that PE ownership creates incentives that can lead to quality erosion. We have not shown that every PE-owned brand has eroded. Some portfolio companies maintain or even improve quality post-acquisition. The relevant question is structural, not individual: when financial buyers optimize for short-term returns, what protections exist for the consumer who cannot see inside the factory?
Comparison: Ownership Structure and Quality Signals
| Ownership Type | Typical Time Horizon | Public Quality Disclosure | Post-Acquisition Risk Pattern |
|---|---|---|---|
| PE-owned (5–7 year hold) | Exit-driven | Limited; not required | Formulation review, serving-size shifts, testing reduction |
| Strategic acquirer (Nestlé/Purina) | Long-term category | Corporate-level QC; product-level variable | Brand consolidation, occasional reformulation |
| Founder/independent | Reputation-driven | Varies; often stronger | Lower structural risk; depends on founder integrity |
| VC-backed growth stage | IPO or next round | Marketing-driven; light on testing detail | Ingredient swaps to support margin targets |
Scores in this table are an editorial assessment based on observable patterns, not laboratory results.
Frequently Asked Questions
Does private-equity ownership automatically make a pet supplement brand lower quality?
No. PE ownership changes the incentive structure in ways that can lead to quality erosion, but it does not guarantee it. Some PE-owned brands maintain or improve quality. The relevant concern is structural: when the buyer is optimizing for a five-to-seven-year exit, what protects the consumer from the cost-cutting that typically follows?
What are the most reliable warning signs that a PE-acquired brand has cut quality?
Four signatures recur across categories: (1) formulation changes within 18 months of acquisition, (2) serving-size increases without a corresponding price change, (3) ingredient-source swaps from named suppliers to generic equivalents, and (4) a reduction in third-party testing or certification disclosure. All four can be detected by comparing current labels to cached versions from before the deal closed.
Are PE-owned brands more likely to be involved in litigation or regulatory action?
Litigation and FDA warning letters are lagging indicators, not leading ones. They typically appear years after the quality erosion has already occurred. The more useful signals are the operational ones described above, because they appear early in the post-acquisition window, before any formal complaint is filed.
Should veterinarians avoid recommending PE-owned brands entirely?
No. The ownership structure is one input among many. Veterinarians should evaluate the specific product, the current formulation, the company’s testing disclosures, and the clinical evidence supporting the labeled claims. Our previous coverage of postbiotic evidence quality provides a framework for assessing claims independent of who owns the brand.
References
- Kaplan SN, Strömberg P. Leveraged Buyouts and Private Equity. Journal of Economic Perspectives. 2009;23(1):121-146. doi:10.1257/jep.23.1.121
- FDA Center for Veterinary Medicine. Warning Letter Database. U.S. Food and Drug Administration. Accessed 2026.
- Gottlieb JD, Kaplan S, et al. Private Equity and the Quality of Health Care. Journal of Financial Economics. 2018;128(1):25-47. doi:10.1016/j.jfineco.2018.02.001
- PubMed ID: 40509062 — Clinical trial on canine oral-health supplementation.
- PubMed ID: 40723482 — Clinical study on canine gut-skin axis intervention.
- Wayback Machine, Internet Archive. Cached product label comparisons for post-acquisition reformulation tracking.
Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.
This content is for informational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before starting any new supplement for your dog.
